研究業績（原著論文のみ）/ Publications(Original Articles only)
2017年度
Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).
Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.
BMC Cancer.2017.17(1):674.
Lymph node metastatic melanoma from ungual melanoma: Identification of somatic mutations in KIT and LZTR1.
Oiso N, Sakai K, Narita T, Yanagihara S, Nishio K, Kawada A.
J Dermatol.[E-pub ahead of print]
Prospective replication study implicates the catechol-O-methyltransferase Val158Met polymorphism as a biomarker for the response to morphine in patients with cancer.
Matsuoka H, Makimura C, Koyama A, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.
Biomed Rep. 2017 Aug.7(4):380-384.
Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation.
Udo E, Furusato B, Sakai K, Prentice LM, Tanaka T, Kitamura Y, Tsuchiya T, Yamasaki N, Nagayasu T, Nishio K, Fukuoka J.
Diagn Pathol. 2017. 12(1):62.
Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms.
Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, Serizawa K, Rai S, Morita Y, Hanamoto H, Tsubaki K, Nishio K, Matsumura I.
Int J Hematol. [E-pub ahead of print]
Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status.
Sakai K, Ukita M, Schmidt J, Wu L, De Velasco MA, Roter A, Jevons L, Nishio K, Mandai M.
Cancer Lett. 2017 Jul 19.1;405.22-28.
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura T, Nishio K, Nakagawa K, Tsurutani J.
Int J Cancer. 2017 Jul 12.141(8):1682-1689.
A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.
Clin Lung Cancer. [E-pub ahead of print]
Incidence of carnitine deficiency in patients with cancer pain: A pilot study.
Sakai K, Matsuoka H, Ohtake Y, Makimura C, Izumi H, Fujita Y, Otsuka M, Tsurutani J, Nishio K, Nakagawa K, Koyama A.
Mol Clin Oncol.2017.06. 6(3):331-333.
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib.
Banno E, Togashi Y, de Velasco MA, Mizukami T, Nakamura Y, Terashima M, Sakai K, Fujita Y, Kamata K, Kitano M, Kudo M, Nishio K.
Int J Oncol.2017.06. 50(6):2049-2058
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S,D761Y, and T854A.
Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
BMC Cancer.2017.04. 17(1):281
A Randomized Study of FOLFIRI plus either Panitumumab or Bevacizumab for Wild-Type KRAS Colorectal Cancer-WJOG 6210G.
Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.
Cancer Sci, in press, 2016.
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Tsubaki M, Takeda T, Kino T, Sakai K, Itoh T, Imano M, Nakayama T, Nishio K, Satou T, Nishida S.
Oncotarget.2017.06.8(24):38717-38730.
Tumor Immune Microenvironment and Nivolumab Efficacy in EGFR Mutation-Positive Non-Small Cell Lung Cancer Based on T790M Status after Disease Progression During EGFR-TKI Treatment.
Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, Nonagase Y, Takahama T, Tanizaki J, Tanaka K, Yoshida T, Tanimura K, Takeda M, Yoshioka H, Ishida T, Mitsudomi T, Nishio K, Nakagawa K.
Ann Oncol.2017.04.8(24):38717-38730.[Epub ahead of print]
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Matsuoka H, Kaneda H, Sakai K, Koyama A, Nishio K, Nakagawa K.
Clin Lung Cancer.2017.01.18(1):e85-e87.
The H3K27 demethylase, Utx, regulates adipogenesis in a differentiation stage-dependent manner.
Ota K, Tong KI, Goto K, Tomida S, Komuro A, Wang Z, Nishio K, Okada H.
PLoS One.2017.05.12(3):e0173713.
Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine.
Matsuoka H, Yoshiuchi K, Koyama A, Makimura C, Fujita Y, Tsurutani J, Sakai K, Sakamoto R, Nishio K, Nakagawa K.
Int J Behav Med.2017.08.24(4):535-541.
Phylloid hypomelanosis associated with a mosaic trisomy 13 in the 13q31.3-qter region: atypical phylloid distribution and typical hypomelanosis.
Oiso N, Sakai K, Nishio K, Kawada A.
Pigment Cell Melanoma Res.2017.05.30(2):269-272.
Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer.
Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.
Mol Cancer Ther.2017.02.16(2):357-364.
Identification of a FGFR3-TACC3 fusion in esophageal cancer.
T. Mizukami, K. Sakai, S. Naruki, T. Taniyama, Y. Horie, N. Izawa, T. Tsuda, T.Fujino, N. Boku, H. Yasuda, T. Fukunaga, T. Eguchi Nakajima, K. Nishio.
Ann Oncol.2017.02. 28(2):437-438.
2016年度
Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation.
Tanizaki J, Banno E, Togashi Y, Hayashi H, Sakai K, Takeda M, Kaneda H, Nishio K, Nakagawa K.
Lung Cancer.2016.11.101:11-15.
Association of EGFR exon 19 deletion and EGFR-TKI treatment duration with frequency of T790M mutation in EGFR-mutant lung cancer patients.
Matsuo N, Azuma K, Sakai K, Kawahara A, Ishii H, Tokito T, Kinoshita T, Yamada K, Nishio K, Hoshino T.
Sci Rep (in press)
MEK inhibitors against MET-amplified non-small cell lung cancer.
Chiba M, Togashi Y, Tomida S, Mizuuchi H, Nakamura Y, Banno E, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.
Int J Oncol. 2016 Oct 17. doi: 10.3892/ijo.2016.3736.
Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.
Nagai T, Arao T, Nishio K, Matsumoto K, Hagiwara S, Sakurai T, Minami Y, Ida H, Ueshima K, Nishida N, Sakai K, Saijo N, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Haji S, Kudo M.
Dig Dis. 2016;34(6):702-707.
A Randomized Study of FOLFIRI plus either Panitumumab or Bevacizumab for Wild-Type KRAS Colorectal Cancer-WJOG 6210G.
Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.
Cancer Sci, in press, 2016.
Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.
Ann Oncol, in press, 2016.
Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFRmutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib.
Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasakara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K.
ESMO Open, in press, 2016.
Tumor volume determines the feasibility of cell-free DNA sequencing for mutation detection in non-small cell lung cancer.
Ohira T, Sakai K, Matsubayashi J, Kajiwara Nk Kakihara M, Hagiwara M, Hibi M, Yoshioka K, Maeda J, Ohtani K, Nagao T, Nishio K, Ikeda N.
Cancer Sci, 2016.[Epub ahead of print]
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib.
Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K.
Cancer Sci, 2016.[Epub ahead of print]
Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T, Sakai K, Takeda M, Azuma K, Hida T, Hirabayashi M, Oguri T, Tanaka H, Ebi N, Sawa T, Bessho A, Tachihara M, Akamatsu H, Bandoh S, Himeji D, Ohira T, Shimokawa M, Nakanishi Y, Nakagawa K, Nishio K.
Oncotarget, E-pub ahead of print, 2016.
Afatinib against esophageal or head-and-neck cell squamous carcinoma: significance of activating oncogenic HER4 mutations in HNSCC.
Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K.
Mol Cancer Ther, 15(8): 1988-97, 2016.8
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Kaibori M, Sakai K, Ishizaki M, Matsushima H, De Velasco MA, Matsui K, Iida H, Kitade H, Kwon AH, Nagano H, Wada H, Haji S, Tsukamoto T, Kanazawa A, Takeda Y, Takemura S, Kubo S, Nishio K.
Oncotarget, in press, 2016.
Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E, Togashi Y, Nakamura Y, Chiba M, Kobayashi Y, Hayashi H, Terashima M, Velasco MA, Sakai K, Yoshihiko F, Mitsudomi T, Nishio K.
Cancer Sci, 107(8): 1134-40, 2016.8.
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
Sato K, Suda K, Shimizu S, Sakai K, Mizuuchi H, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.
PLoS One, 11(4): e0154186, 2016.4.
Characterization of the cytotoxic activity of [2]rotaxane (TRO-A0001), a novel supramolecular compound, in cancer cells.
Fujita Y, Kimura M, Sato H, Takata T, Ono N, Nishio K.
Arch Pharm Res.39(6): 825-32, 2016.1
Oncogene swap as a novel mechanism of acquired resistance to EGFR-tyrosine kinase inhibitor in lung cancer.
Mizuuchi H, Suda K, Murakami I, Sakai K, Sato K, Kobayashi Y, Shimoji M, Chiba M, Sesumi Y, Tomizawa K, Takemoto T, Sekido Y, Nishio K, Mitsudomi T.
Cancer Sci.107(4):461-8.2016.4
Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Watanabe S, Takeda M, Takahama T, Iwasa T, Tsurutani J, Tanizaki J, Shimizu T, Sakai K, Wada Y, Isogai N, Nishio K, Nakagawa K.
Invest New Drugs.34(3):396-4.2016.6
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: a subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T, Togashi Y, Banno E, Terashima M, Velasco MA, Sakai K, Nishio K, et al.
Molecular Carcinogenesis. 2016.[Epub ahead of print]
Functional analyses of mutations in receptor tyrosine kinase genes in non-small cell lung cancer: double-edged sword of DDR2.
Terashima M, Togashi Y, Sato K, Mizuuchi H, Sakai K, Suda K, Nakamura Y, Banno E, Hayashi H, De Velasco MA, Fujita Y, Tomida S, Mitsudomi T, Nishio K.
Clin Cancer Res. 22(14): 3663-71, 2016.
Genome sequencing for non-small cell lung cancer identifies a basis for nintedanib sensitivity.
Takeda M, Sakai K, Okamoto K, Hayashi H, Tanaka K, Shimizu T, Nishio K, Nakagawa K.
Ann Oncol;27(4):748-50. 2016 4.
Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
Develasco MA, Kura Y, Yoshikawa K, Nishio K, Davies BR, Uemura H.
Oncotarget. 7(13):15959-76, 2016.3
Heterogeneity in resistance mechanisms causes shorter duration ofepidermal growth factor receptor kinase inhibitor treatment in lungcancer.
Suda K, Murakami I, Sakai K, Tomizawa K, Mizuuchi H, Sato K, Nishio K, Mitsudomi T.
Lung Cancer. 91: 36-40, 2016.
Overexpression of CD55 from Barrett's esophagus is associated with esophageal adenocarcinoma risk.
Murao T, Shiotani A, Fujita Y, Yamanaka Y, Kamada T, Manabe N, Hata J, Nishio K, Haruma K.
J Gastroenterol Hepatol, 2016 Jan;31(1):99-106.